Aptose to Report First Quarter 2021 Financial Results and Hold Conference Call on Tuesday, May 4, 2021
26 avr. 2021 16h02 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, April 26, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the...
Aptose to Present at Canaccord Genuity 2021 Horizons in Oncology Virtual Conference
08 avr. 2021 07h30 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, April 08, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...
Aptose Reports Results for the Fourth Quarter and Full Year 2020
23 mars 2021 16h01 HE
|
Aptose Biosciences, Inc.
- Conference call and webcast at 5pm EDT today - - Company announces resignation of CFO Gregory Chow - - Luxeptinib (CG-806) continues dose escalation and evidence of clinical activity - SAN DIEGO...
Aptose Presents Highlights from ASH and Corporate Update Event
06 déc. 2020 17h30 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Dec. 06, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today released highlights from a corporate update event held on Sunday, December...
Aptose to Hold Corporate Update Sunday, December 6th
01 déc. 2020 07h30 HE
|
Aptose Biosciences, Inc.
Corporate event to provide clinical update for CG-806 in AML and B-cell Cancers Poster Presentations for CG-806 and APTO-253 are scheduled for December 5th and 6th at 2020 ASH Annual Meeting...
Aptose Reports Results for the Third Quarter 2020
10 nov. 2020 16h01 HE
|
Aptose Biosciences, Inc.
Dosing Initiated in CG-806 Phase 1 a/b Study in AML Patients at 450mg Dose Level Nodal Reductions Observed and Dosing Continues in CG-806 Phase 1 a/b Study in CLL Patients Dosing Continues in...
Aptose to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
15 sept. 2020 07h30 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...
Aptose Biosciences to Present at Canaccord Genuity 40th Annual Growth Conference
06 août 2020 07h30 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the...
Aptose to Release Second Quarter Ended June 30, 2020 Financial Results and Hold Conference Call on August 4, 2020
21 juil. 2020 16h01 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, July 21, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...
Aptose Announces Pricing of Public Offering of Common Shares
15 juil. 2020 22h49 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, July 15, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced that it priced its previously announced...